Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)

Mathias J Rummel, MD PhD, Christian Lerchenmüller, MD, Manfred Hensel, MD, Martin Goerner, MD, Christian Buske, MD PhD, Holger Schulz, Burkhard Schmidt, MD, Georgi Kojouharoff, MD, Elisabeth Lange, MD, Wolfgang Willenbacher, MD PhD, Jan Dürig, Erik Engel, Frank Kauff, Jürgen Barth, Alexander Christoph Burchardt, MD, Axel Hinke, PhD, Jasmin Wupperfeld, Richard Greil, MD

Blood (2019) 134 (Supplement_1): 343.

https://doi.org/10.1182/blood-2019-121909

Published: 2019

Journal Articles

Prognostic Value of Circulating Bcl-2/Igh Levels before and after Treatment in 415 Patients with Advanced Follicular Lymphoma Receiving First-Line Immuno-Chemotherapy in 2 Prospective StiL Trials - the Effect of Rituximab Maintenance

Guido Kobbe, Sabrina Pechtel, Fabian Zohren, MD PhD, Jürgen Barth, Alexander Christoph Burchardt, MD, Christian Buske, MD, Ariane Dienst, MD, Ulrich Germing, MD, Richard Greil, MD, Bernd Hertenstein, MD, Frank Kauff, Michael Koenigsmann, MD, Christian Lerchenmüller, MD, Thomas Michael Schroeder, MD PhD, Rainer Haas, MD, Mathias J Rummel, MD PhD

Blood (2018) 132 (Supplement 1): 4149.

https://doi.org/10.1182/blood-2018-99-118750

Published: 2018

Journal Articles

Four Versus Two Years of Rituximab Maintenance (R-maintenance) Following Bendamustine Plus Rituximab (B-R): Initial Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN study)

Mathias J Rummel, Christian Buske, MD, Bernd Hertenstein, MD, Christian Lerchenmüller, MD, Michael Koenigsmann, MD, Elisabeth Lange, MD, Manfred Reeb, MD, Ulrich Kaiser, MD, Christina Balser, MD, Dirk Behringer, MD, Jan Dürig, MD, Tobias Gaska, MD, Georg Maschmeyer, MD, Georg Schliesser, MD, Alexander Christoph Burchardt, MD, Juergen Barth, Frank Kauff, Axel Hinke, PhD, Richard Greil, MD

Blood (2017) 130 (Supplement 1): 483.

https://doi.org/10.1182/blood.V130.Suppl_1.483.483

Published: 2017

Journal Articles

Temsirolimus in Combination with Bendamustine and Rituximab (BeRT) for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Final Phase I/II Results

Georg Hess, MD, Wagner Karola, Paul LaRosee, MD, Ulrich Keller, Johannes Atta, Mathias Witzens-Harig, MD, Anne Crombé, Christoph Medler, Peter Borchmann, MD, Ulrich Bitz, MD, Christian Lerchenmüller, MD, Matthias Theobald, MD, Martin H. Dreyling, MD PhD

Blood (2016) 128 (22): 2977.

https://doi.org/10.1182/blood.V128.22.2977.2977

Published: 2016

Journal Articles

Prognosis of Myelodysplastic Syndromes (MDS) in Patients in the Age of 80 Years and Older: Data from the Regular Care MDS Registry in Germany

H. Tilman Steinmetz, MD, Roja Wahdat, Burkhard Haastert, PhD, Annette Sauer, MD, Bernd Lathan, MD, Christian Lerchenmüller, MD, Hans Tesch, Professor, Ulrich Germing, Stephan Schmitz, Professor

Blood (2016) 128 (22): 4333.

https://doi.org/10.1182/blood.V128.22.4333.4333

Published: 2016

Journal Articles

Bendamustine Plus Rituximab Followed By Rituximab Maintenance for Patients with Untreated Advanced Follicular Lymphomas. Results from the StiL NHL 7-2008 Trial (MAINTAIN trial) (ClinicalTrials.gov Identifier: NCT00877214)

Blood (2014) 124 (21): 3052.

https://doi.org/10.1182/blood.V124.21.3052.3052

Published: 2014

NARROW

Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)

Prognostic Value of Circulating Bcl-2/Igh Levels before and after Treatment in 415 Patients with Advanced Follicular Lymphoma Receiving First-Line Immuno-Chemotherapy in 2 Prospective StiL Trials - the Effect of Rituximab Maintenance

Four Versus Two Years of Rituximab Maintenance (R-maintenance) Following Bendamustine Plus Rituximab (B-R): Initial Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN study)

Temsirolimus in Combination with Bendamustine and Rituximab (BeRT) for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Final Phase I/II Results

Prognosis of Myelodysplastic Syndromes (MDS) in Patients in the Age of 80 Years and Older: Data from the Regular Care MDS Registry in Germany

Bendamustine Plus Rituximab Followed By Rituximab Maintenance for Patients with Untreated Advanced Follicular Lymphomas. Results from the StiL NHL 7-2008 Trial (MAINTAIN trial) (ClinicalTrials.gov Identifier: NCT00877214)

Email alerts

ASH Publications

American Society of Hematology

Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)

Prognostic Value of Circulating Bcl-2/Igh Levels before and after Treatment in 415 Patients with Advanced Follicular Lymphoma Receiving First-Line Immuno-Chemotherapy in 2 Prospective StiL Trials - the Effect of Rituximab Maintenance

Four Versus Two Years of Rituximab Maintenance (R-maintenance) Following Bendamustine Plus Rituximab (B-R): Initial Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN study)

Temsirolimus in Combination with Bendamustine and Rituximab (BeRT) for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Final Phase I/II Results

Prognosis of Myelodysplastic Syndromes (MDS) in Patients in the Age of 80 Years and Older: Data from the Regular Care MDS Registry in Germany

Bendamustine Plus Rituximab Followed By Rituximab Maintenance for Patients with Untreated Advanced Follicular Lymphomas. Results from the StiL NHL 7-2008 Trial (MAINTAIN trial) (ClinicalTrials.gov Identifier: NCT00877214)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only